<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405402</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-PRO-TRANSFU-DREPANO 1</org_study_id>
    <nct_id>NCT03405402</nct_id>
  </id_info>
  <brief_title>Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization</brief_title>
  <official_title>Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanane EL KENZ</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell patients have a high prevalence of alloimmunization. This high rate of&#xD;
      alloimmunization can be partially explained by the existence of an antigenic difference&#xD;
      between the predominantly Caucasian donor population and the sickle cell patients of African&#xD;
      origin. Genetic and environmental risk factors have also been described.&#xD;
&#xD;
      The main risk factors that have been shown in retrospective or cross-sectional studies are&#xD;
      some HLA alleles, the age of the patient, the number of leukocyte-depleted erythrocyte&#xD;
      concentrates (CED) transfused, the number of transfusion episodes, the age of the CEDs, the&#xD;
      existence of an inflammatory event at the time of transfusion and the presence of&#xD;
      anti-erythrocyte autoantibodies.There is also evidence of an impaired TH response but the&#xD;
      underlying immunological mechanism is not fully understood.&#xD;
&#xD;
      The aim of this study is to study the prevalence and the risk factors for anti-erythrocyte&#xD;
      alloimmunization and to try to understand the immunological mechanisms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 13, 2018</start_date>
  <completion_date type="Actual">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">August 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irregular antibodies</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Presence/abscence of irregular antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irregular antibodies</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Presence/abscence of irregular antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>CRP dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Cytokine dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Cytokine dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heme oxygenase</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Heme oxygenase dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heme oxygenase</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Heme oxygenase dosage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte typing</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Lymphocyte typing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte typing</measure>
    <time_frame>Between 2 to 4 weeks after blood transfusion</time_frame>
    <description>Lymphocyte typing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sex</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic or acute blood transfusion</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Blood transfusions planned at regular intervals of time (chronic transfusions) or performed in reaction to a medical issue (acute transfusion).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion indication</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Medical reason explaining the necessity of a blood transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood donor ethnicity</measure>
    <time_frame>1 hour before blood transfusion</time_frame>
    <description>Blood donor ethnicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">173</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allo-immunization detected (positive response for irregular antibodies 2 to 4 weeks after a blood transfusion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Allo-immunization not detected</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Sickle cell disease patients treated within the CHU Brugmann or Queen Fabiola Children's&#xD;
        Hospital&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Deleers, Ph Biol</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUDERF</name>
      <address>
        <city>Brussel</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Hanane EL KENZ</investigator_full_name>
    <investigator_title>Head of Blood Bank</investigator_title>
  </responsible_party>
  <keyword>Sickle cell disease</keyword>
  <keyword>Allo-immunization</keyword>
  <keyword>Blood transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

